Hope S. Rugo, Paula Klein, Susan A. Melin, Sara A. Hurvitz, Michelle Melisko, Ralph B. D’Agostino, Amy DeLuca, Melissa Bourestom, Tessa Cigler
Scalp cooling can prevent hair loss in women with early stage breast cancer receiving neo/adjuvant chemotherapy.
Data from 2 prospective trials 1,2 led to FDA clearance of 2 automated scalp cooling devices to prevent chemotherapy induced-alopecia (CIA).
Although scalp metastases from breast cancer are rare, historical concerns about scalp cooling included a theoretical increase in risk of recurrence in scalp due to reduced delivery of chemotherapy to the scalp.
In a meta analysis of reported scalp cooling trials scalp metastases were rare (<1%) and were not increased with in patients who used scalp cooling.
We report long term safety follow up from the Dignitana study.
